Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study
Background: Cystic fibrosis (CF) is characterized by chronic neutrophilic inflammation in the airways. Elexacaftor/tezacaftor/ivacaftor (ETI) therapy has demonstrably improved clinical outcomes and quality of life in people with CF (pwCF), but its effects on systemic inflammatory parameters remain u...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publishing
2025-02-01
|
| Collection: | Therapeutic Advances in Respiratory Disease |
| Accès en ligne: | https://doi.org/10.1177/17534666251314706 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|